|Other names||Artesunate/pyronaridine tetraphosphate|
|Defined daily dose||not established|
Artesunate/pyronaridine, sold under the brand name Pyramax, is a fixed-dose combination medication for the treatment of malaria. It can be used for malaria of both the P. falciparum and P. vivax types. It combines artesunate and pyronaridine. It is taken by mouth.
The combination is generally well tolerated. Side effects may include headache, vomiting, or cough. Use in those with severe liver disease or kidney disease is not recommended. Use is not generally recommended in early pregnancy. However, there are no other options and if treatment may save the mother's life it may be used. The two components work by different mechanisms.
It is on the World Health Organization's List of Essential Medicines. In 2010 the wholesale cost of a course of treatment in the developing world was between 0.55 and 2.18 USD.
A 2019 review found that the combination compared well to artemether/lumefantrine. Benefits also appear similar to mefloquine together with artesunate. It is not recommended for the prevention of malaria.
- "Application for inclusion in the WHO Model List of essential medicines" (PDF). WHO. Nov 2010. Retrieved 29 June 2017.
- "Pyramax 180 mg/60 mg Film-coated tablet" (PDF). EMA. Retrieved 13 December 2017.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 11 September 2020. CS1 maint: discouraged parameter (link)
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- Pryce J, Hine P (January 2019). "Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria". The Cochrane Database of Systematic Reviews. 1: CD006404. doi:10.1002/14651858.CD006404.pub3. PMC 6353203. PMID 30620055.